Osteonecrosis of the jaw (ONJ) can be associated with nitrogen-containing bisphosphonates (NBPs) therapy. Various mechanisms of NBP-associated ONJ have been proposed and there is currently no consensus of the underlying pathogenesis. The detailed medical and dental histories of 30 ONJ patients treated with NBPs for malignant diseases (24) or osteoporosis (6) were analyzed. The necrotic bone was resected and analyzed histologically after demineralization. In 10 patients the perinecrotic bone was also resected and processed without demineralization. Alveolar bone samples from 5 healthy patients were used as controls. In 14 ONJ patients, serial technetium-99m-methylene diphosphonate scintigraphic scans were also available and confronted to the other data. Strong radionuclide uptake was detected in some patients several months before clinical diagnosis of ONJ. The medullary spaces of the necrotic bone were filled with bacterial aggregates. In the perinecrotic bone, the bacteria-free bone marrow characteristically showed an inflammatory reaction. The number of medullary inflammatory cells taken as an index of inflammation allowed us to discriminate two inflammation grades in the ONJ samples. Low-grade inflammation, characterized by marrow fibrosis and low inflammatory cells infiltration, increased numbers of TRAP + monoand multineacleated cells was seen in patients with bone exposure b 2 cm 2 . High-grade inflammation, associated with larger lesions, showed amounts of tartrate-resistant acid phosphatase + /calcitonin receptor − mono-and multinucleated cells, osteocyte apoptosis, hypervascularization and high inflammatory cell infiltration. The clinical extent of ONJ was statistically linked to the numbers of inflammatory cell. Taken together these data suggest that bone necrosis precedes clinical onset and is an inflammation-associated process. We hypothesize that from an initial focus, bone damage spreads centrifugally, both deeper into the jaw and towards the mucosa before the oral bone exposure and the clinical diagnosis of ONJ.
Introduction
Postmenopausal osteoporosis, Paget's disease, and metastatic bone diseases are characterized by high bone turnover. One of the most efficient ways to treat these affections is the use of bisphosphonates. Among them nitrogen-containing bisphosphonates (NBPs) are the most potent in inhibiting bone resorption [1] . Osteonecrosis of the jaw (ONJ) associated with NBPs therapy is a recently described detrimental effect first reported in 2003 [2] . ONJ is characterized by an area of exposed bone in the maxillofacial region that does not heal within 8 weeks, in a patient who has no metastasis or radiation therapy in the craniofacial region [3] . High repeated doses of NBPs administered intravenously to cancer patients, are most frequently associated with ONJ [4] [5] [6] . In contrast, patients receiving oral NBPs for osteoporosis are less prone to ONJ [7] .
Various mechanisms of NBP-associated ONJ have been proposed. It is generally admitted that this adverse effect targets the jaws because they concentrate NBPs owing to their high bone turnover compared with other anatomical sites [8] , and bisphosphonate toxicity on osteoclasts [9] . It has also been proposed that NBPs may have an antiangiogenic effect, reducing blood flow and thus inducing bone cell necrosis and apoptosis [10, 11] . One alternative explanation is an "outside-in" process in which mucosal damage provides oral bacteria with access to the underlying bone, leading to bone infection and necrosis [12] . NBP soft tissue toxicity would thus be the trigger leading to necrosis of the mucosa and bone [13] [14] [15] . Genetic variations may also constitute a risk factor; it was recently shown that ONJ is associated with gene polymorphisms in multiple myeloma patients [16, 17] . Moreover, the primary disease is probably a predisposing factor as frequency of ONJ is 2 fold higher in multiple myeloma than in breast cancers despite similar NBPs treatments [6] . It is likely that ONJ results from a conjunction of environmental, metabolic and genetic factors. The role of NBPs in the process was suggested in dogs receiving clinically relevant daily oral alendronate treatment for 3 years that developed mandible bone matrix necrosis without oral exposure [18] .
As there is currently no consensus on its underlying mechanism, ONJ task forces have called for more clinical and basic research [3, 7, 19, 20] . The aim of the present study was to examine clinical and histopathological features of patients with ONJ in an attempt to better understand the pathogenesis of this disorder.
Patients and methods

Patients
Thirty bisphosphonate-treated patients with persistent oral bone exposure, referred by dental practitioners or oncologists to the Department of Stomatology and Oral Surgery of the University Hospitals of Geneva (Switzerland), were enrolled in this study. The patients were anonymously included in the study that complied with the Declaration of Helsinki. Each patient's detailed medical and dental histories were analyzed. Criteria for diagnosis of bisphosphonaterelated osteonecrosis of the jaw, according to the ASBMR [3] , were:
− ongoing intravenous or oral bisphosphonate therapy, − no history of maxillofacial radiation therapy, − oral exposure of necrotic bone at the maxilla or the mandible for 8 weeks without healing, and − exclusion by histological examination of bone metastases of a primary malignant disease and confirmation of bone necrosis.
Before the initial consultation in the department, the patients had been diagnosed with chronic refractory osteomyelitis and treated with repeated courses of antibiotics and analgesics. Antecedents of local infectious conditions, especially periodontal status, were carefully assessed with past clinical and X-ray data provided by the dental practitioners. An orthopantomogram (OPG) was systematically done to rule out local etiologies. Serial technetium-99m-methylene diphosphonate scintigraphic scans ( 99 Tc m -MDP) done prior ONJ diagnosis were available for 14 patients treated for bone metastases of solid tumors ( Fig. 1 ).
Local ONJ treatment strategies
Three treatment strategies based on the size of bone exposure were used. Patients with mild ONJ (bone exposure b 1 cm 2 ) and patients who refused invasive procedures were treated conservatively with systemic antibiotics and local antiseptics, and analgesics if necessary. Patients with moderate ONJ (1 cm 2 N bone exposure b 2 cm 2 ) had minimal invasive surgery consisting of decortication and flattening of rough necrotic bone, fibrin glue coverage, closure with mucosal tissue, and medical treatment as described above. Patients with severe ONJ (bone exposure N 2 cm 2 ) had a more extensive procedure, including bone resection and curettage of the surrounding bone, and local and medical treatments as described above.
All the patients were closely monitored, every 3 or 4 months the first year and then every 6 months. An OPG was performed every 6 months. Outcome (extension, improvement or healing of mucosal and bone tissues) was evaluated clinically and radiographically. Mucosal healing was defined as complete mucosal closure, mucosal improvement as a decrease in the area of exposed bone, and mucosal spreading as an increase of this area.
Processing of biopsy specimens
Necrotic bone was resected in 26 patients and was examined after formaldehyde fixation, formic acid 10% demineralization, paraffin embedding, sectioning, hematoxylin-eosin or PAS stainings. In 10 patients, the perinecrotic bone was also sampled, it was fixed in 70% ethanol, dehydrated and embedded without previous demineralization in methylmethacrylate (Merck, Darmstadt, Germany). Bone samples taken from 5 healthy alendronate-treated patients during dental implant surgery were processed in the same way and used for control. Series of 4-μm-thick sections were stained with toluidine blue (pH 4.3) or hematoxylin-eosin or processed for tartrate-resistant acid phosphatase (TRAP) revelation and immunohistochemistry. TRAP was detected by using hexazotized pararosanilin (Sigma, St Louis, MO) and naphthol ASTR phosphate (Sigma) to reveal osteoclasts; non-osteoclastic acid phosphatase was inhibited by adding 100 mMol/L L(+)-tartaric acid (Sigma) to the substrate solution. A mouse monoclonal antibody against human calcitonin receptor (CTR; MCA2191, AbD Serotec, Düsseldorf, Germany), a rabbit polyclonal antibody against caspase-3 to reveal apoptotic cells (12-01-16362 ; Biocarta, San Diego, CA), and a rabbit polyclonal antibody against von Willebrand factor (F3520, Sigma) to reveal vascular structures, were used. The sections were incubated with the primary antibodies (CTR 1:25; caspase-3 1:500; von Willebrand factor 1:400, at room temperature in a moist chamber overnight) and then with secondary biotinylated antibodies (horse anti-mouse or goat anti-rabbit IgG, both from Vector; 1:200, 90 min at room temperature). After treatment with 3% hydrogen peroxide for 10 min and avidin-biotin peroxidase complex (ABC Vectastain Kit, Vector, Burlingame, CA) for 1 h, the chromogen 3,3′-diaminobenzidine tetrahydrochloride (Sigma) was added. Negative controls were prepared by omitting the primary A 78-year-old woman with breast cancer and temporal bone metastases receiving IV zoledronic acid (4 mg/month for 11 months) showed spots of radionuclide uptake in the anterior part of the maxilla and in the left mandible corresponding to recent tooth extractions (arrows) and to an infectious dental focus (arrowheads). Patient 2 (C to F). A 60-year-old woman with breast cancer and bone metastases receiving IV zoledronic acid (4 mg/month for 20 months). In September 2005, two left lower molars (C) became painful and mobile, with no radiographic evidence of an infectious process; they were extracted. In March 2006, the sockets of the two molars were still open, and no signs of bone healing were discernible on the X-ray (D). Clinically, necrotic bone was exposed to the oral environment and extended to a large part of the left mandible (E). The patient died one month later. Successive 99 Tc m -MDP scintigraphies (F) show the progression of radionuclide uptake in the mandible: in April 2004, two spots of radionuclide uptake (arrows) were visible; the uptake progressed backwards on the left side and the spots merged; after the dental extractions, most of the mandible was involved. Patient 3 (G to M). A 45-year-old man with multiple myeloma treated with IV pamidronate (30 mg/month for 78 months), then zoledronic acid (4 mg/month for 8 months). In April 1999 (G), after 2 years of pamidronate therapy, there was no evidence of jaw involvement. Five years later (H), the patient self-extracted a very mobile and painful second left lower molar. Oral bone exposure occurred. At the same time, CT scan (I) showed, besides the empty molar socket (arrowhead), interruption of oral cortex continuity in the right lower molar region (arrows), with no clinical manifestations. One month later, scintigraphy showed two distinct spots of radionuclide uptake in the mandible (J), the left (Le) one was large and corresponded to the oral bone exposure that occurred after molar self-extraction, whereas the smaller right (Ri) one (arrows), superimposable on the CT image, occurred in a clinically unaffected zone. In June 2005, another molar was lost (K) and the necrotic bone exposure extended to this zone (L). The last scintigraphy showed the growth of the left spot and the persistence of the right spot (M); the latter did not become clinically manifest, as the patient died two months later. antibody, replacing the primary antibody with rabbit non-immune serum at the same dilution, and using an irrelevant secondary antibody.
Morphometry was performed in the non-demineralized samples.
Statistical analysis
Data were compared using non-parametric tests (Kruskal-Wallis followed, if significant, by group comparisons with the MannWhitney U test). The association of clinical extent of ONJ with the numbers of inflammatory cells was assessed using the Wilcoxon test. Differences were considered significant at P b 0.05. Data are expressed as means ± SEM.
Results
Characteristics of the patients (Tables 1 and 2)
The distribution of the patients according to the initial pathology and potential co-morbidity factors is shown in Table 1 . The cancer patients had previously received various cancer treatments but no maxillofacial radiation therapy. The female:male sex ratio was 2:1. The mean age was 69.9 ± 2.4 years (females: 68.9 ± 2.9; males: 71.3 ± 4.8). The control patients (4 women and 1 man) were treated for osteoporosis. The mean age was 73.8 ± 2.6 years (females: 72.2 ± 2.7; male: 80); among these patients 1 was active smoker and another one diabetic ( Table 2 ).
Bisphosphonate regimens (Table 2) The cancer patients received intravenous pamidronate or zoledronic acid alone, or sequentially, pamidronate followed by zoledronic acid; one patient received ibandronate after one year of zoledronic acid. Osteoporosis patients received oral alendronate; in one patient, oral alendronate was replaced after 4.5 years by intravenous pamidronate. The average time between NBP initiation and clinical diagnosis of ONJ was shorter with zoledronic acid (median: 19 months, range 5-25) than with pamidronate (median: 32 months, range 13-60), pamidronate/ zoledronic acid (median: 37.5 months, range: 23-87) and alendronate (median: 72 months, range: 44-120). Owing to the strong and longlasting accumulation of bisphosphonates in bone tissue, and because of the different therapeutic protocols, the cumulative dose of bisphosphonates is probably more relevant than the treatment duration. The mean cumulative doses at the time of ONJ diagnosis were 67.2± 15.9 mg for the zoledronic acid, 3252.8± 229.9 mg for the pamidronate,1347.3 ± 249.5 mg+ 72.0± 14.4 mg for the pamidronate/zoledronic acid regimen, and 20608.0 ± 2414.6 mg for the alendronate treatment. In this cohort, no ONJ was recorded under the cumulative dose of 20 mg zoledronic acid, 1170 mg pamidronate and 12320 mg alendronate.
Clinical aspect of osteonecrosis (Table 3) The mandible was affected in 54% of cases, the maxilla in 43%, and both sites simultaneously in 3%. Most lesions (84%) affected the premolar-molar regions, i.e. where the forces of mastication are heavier [21] . ONJ was recorded in 87% of cases in sites of dentoalveolar surgery (mainly tooth extraction). The interval between surgery and ONJ diagnosis ranged from 2 to 6 months. In 13 patients, teeth were extracted for abnormal and painful mobility with no clinical or radiographic signs of dental or periodontal infection; in these cases a generalized subtle widening of the periodontal ligament was discernible by radiography. These signs do not fit in with typical periodontitis features, so we hypothesized that pain and tooth mobility were early manifestations of an already present ONJ. The other dental extractions were due to infections. The remaining 13% of patients were edentulous and did not wear dentures (Table 3) .
In 5 of the 14 patients who had 99 Tc m -MDP scintigraphies, focal jaw uptake of bone-seeking isotopes preceded clinical onset and oral exposure of necrotic bone by several months to more than a year (Fig. 1 ). In the 9 other patients, jaw radionuclide uptake occurred after the extractions. Other causes of radionuclide uptake, including local metastasis, were excluded. An additional series of scintigraphies from 14 age and sex-matched ONJ-free patients was used as control; two of them showed a focal uptake in the jaws, corresponding to infectious dental foci or recent extraction sites (Figs. 1A-B) .
Follow-up (Table 4)
All the patients continued to receive NBPs during follow-up. Owing to the strong and long-lasting accumulation of bisphosphonates in bone tissue and to the benefits of the treatment, the medical team decided to not interrupt the NBP treatment. In fact, no evidence suggests that discontinuation of the bisphosphonate therapy will promote ONJ resolution [3] (Table 4) .
Four patients (13%) were conservatively treated (two patients with mild ONJ and two patients with severe ONJ refusing more invasive procedures); the six patients (20%) with moderate ONJ had minimal invasive surgery. The other 20 patients with severe ONJ (70%) had a more extensive surgical procedure. In the group subjected to conservative approach, mucosal healing and bone stabilization were reached in 2 osteoporotic patients with alendronate alone whereas mucosal improvement and bone spreading were recorded in the 2 patients affected by severe ONJ with pamidronate and zoledronate sequentially. In the 6 patients subjected to minimal invasive surgery, 2 osteoporotics with alendronate alone showed mucosal healing and bone improvement; mucosal closure did not occur and bone condition deteriorated in the 4 others whatever the NBP treatment was. In the 20 remaining patients subjected to a more extensive procedure, all types of outcomes were recorded. No mucosal closure or bone stabilization occurred in the patients receiving zoledronic acid alone.
Histopathological findings
Necrotic bone
In the 26 demineralized samples, necrotic bone showed empty osteocyte lacunae, the medullary spaces were filled with bacterial aggregates (cocci and filaments), and, deeper, by polymorphonuclear leukocytes. Actinomyces colonies were frequent and Candida albicans was occasionally found.
Perinecrotic bone
In the 10 non-demineralized samples, the main feature of perinecrotic bone was an inflammatory reaction in the marrow spaces, with marrow fibrosis, inflammatory cell infiltration, development of the vascular network, and osteocyte apoptosis. Inflammation was evaluated by counting the inflammatory cells. The comparison between the control and ONJ patient samples showed a marked difference (p b 0.01; 29.9 ± 2.9 vs 183.6 ± 82.8 cells/mm 2 , respectively). The large intragroup variation in the perinecrotic bone samples prompted us to visualize their distribution (Fig. 2) . When these groups were statistically compared, they differed significantly (p b 0.01). From these data, two grades of inflammation were distinguished (Fig. 2) . In the low-grade group, the bone surface activities appeared to be slightly modified compared with samples from the controls. TRAP + /CTR + osteoclasts, in contact or not with the bone surface, were frequent (Fig. 3) . The peripheral bone lamellae appeared to be less mineralized than the core of the trabeculae. Osteocytes were seldom caspase-3-positive (Fig. 4) and empty osteocyte lacunae were rare. The medullary spaces showed some fibrosis. Small von Willebrand + vessels were distributed throughout the marrow (Fig. 5 ).
In the high-grade inflammation group, bone formation was no longer visible. TRAP + multinucleated cells in contact with the bone surface were more numerous than in the low-grade samples, and most of them were CTR − (Fig. 3) . Most osteocyte lacunae were empty and the remaining osteocytes were generally apoptotic (Fig. 4) . The medullary spaces were fibrotic. Mono-and multinucleated TRAP + / CTR − cells were numerous (Fig. 3) . The vascular network was strongly increased, and the vessels were large and dilated (Fig. 5) . Low-grade inflammation was mainly seen in patients treated with oral NBPs while high-grade inflammation was most frequent in patients treated with intravenous NBPs.
Morphometric data (Table 5) The control, low-grade and high-grade specimen groups as described above were significantly different for all the parameters, except for the number of Table 5) .
Discussion
ONJ has recently emerged as a serious potential adverse effect of NBP therapy. For the first time, we present data pointing to an association with local inflammation. We also propose that bone necrosis and exposure are preceded by early asymptomatic and infectious-free bone involvement.
The first noteworthy result of this study is the presence in the perinecrotic bone of bone marrow inflammation whose severity is associated with the clinical extent of ONJ. The higher bone marrow inflammation the more severe the ONJ. The tissue underlying necrotic bone showed two grades of inflammation. In the first situation, the inflammatory reaction was mild, and its hallmarks were bone marrow fibrosis and moderate inflammatory cell infiltration without vascular change. The observed stimulation of osteoclast recruitment despite ongoing bisphosphonate treatment may result from this inflammatory state; accordingly, Endo et al. reported that NBP injections in mice increased marrow macrophage and osteoclast numbers [22] . Other In contrast, in the high-grade inflammation sample (C), the vessels are abundant, large and dilated. In the high-grade sample (C), the number of apoptotic osteocytes is strongly increased. Bar = 50 μm.
patients had severe inflammation of the bone marrow with strong inflammatory cell infiltration. Another striking feature was osteocyte apoptosis and empty osteocyte lacunae increasing with the degree of inflammation. Osteocyte apoptosis might then be a consequence of the intense inflammatory reaction. Although NBPs are thought to protect osteocytes from apoptosis, they may be toxic beyond a threshold cumulative dose, as this preventive effect was shown either in vitro or with low doses of NBPs [23] [24] . Interestingly, only osteocytes underwent apoptosis. Another characteristic was an increased number of TRAP + multinucleated cells within the marrow spaces. Marie et al. reported such accumulation of TRAP + multinucleated cells, not in contact with the bone surface, in mice treated with NBPs [25] . TRAP expression is not specific to the osteoclast phenotype, as other monocyte-derived cells, such as activated and inflammatory macrophages, also express TRAP in bone marrow [26] . Macrophages also can fuse to form giant cells able to digest large components or to resorb extracellularly after strongly adhering to the substrate in chronic inflammatory sites; as for osteoclasts, multinucleation amplifies their resorptive ability [27] . These cells share with osteoclasts numerous functional markers and calcitonin receptor expression distinguishes osteoclasts from macrophage polykarions [28] . In our samples, most of the multinucleated cells did not express this marker. These TRAP + /CTR − polykarions probably differentiate in response to strong marrow inflammation and/or as a consequence of NBP treatment itself. Unlike TRAP + /CTR + osteoclasts, these TRAP + / CTR − polykarions may not take up NBPs and would thus be less sensitive to their cellular toxicity. In fact, macrophages can internalize NBPs depending on their endocytic ability and on the soluble pool of NBP available [29] , which is probably low in the medullary spaces. We suspect that the polykaryons are involved in clearing necrotic tissues. The strong inflammation was accompanied by prominent development of medullary vessels. This argues against the assumption that NBPs, and particularly zoledronic acid, reduce bone angiogenesis [10, 11] . Our observation is in keeping with the pronounced boneseeking-isotope uptake, pointing to the persistence of an effective blood supply to the affected site. Accordingly, no differences in genes associated with angiogenesis were reported in multiple myeloma patients with NBPs related ONJ [17] . Thus, defective local circulation is unlikely to be responsible for the necrosis, contrary to previous deductions [19, 30] . The site specificity of ONJ could be attributed to the embryological origin of bone marrow stromal cells (BMSC), indeed Stefanik et al. showed that therapeutically relevant dose of pamidronate promoted in vitro higher RANKL gene expression and osteoclast differentiation by mandible BMSC than by iliac crest BMSC [31] . Moreover, the rate of bisphosphonate binding and incorporation by bone is directly related to the rate of local bone turnover. Alveolar bone and edentulous ridges exhibit high turnover [32, 33] and probably incorporate more NBP than other skeletal sites [13] . By drastically reducing bone turnover, NBPs lead to dose-dependent accumulation of microdamages within the bone matrix [34, 35] , thereby affecting the mechanical properties of bone and reducing its energy-absorption capacity [36] . ONJ may follow microdamage accumulation resulting from mastication loading as microdamage accumulation occurs early during NBP treatment [37] . Osteocytes are sensors of matrix microdamages and control the targeted remodeling by entering apoptosis [38] . As resorption is inhibited by NBPs, the signals emitted by apoptotic osteocytes may trigger an inflammatory process that can be detected in the form of focal radionuclide uptake. NBPs themselves might also induce the inflammatory reaction. Indeed, a transient early acute-phase reaction [39] mediated by stimulated Vγ9Vδ2 T cells occurs after the first NBP administration, but not after subsequent infusions [40] . NBPs may act on cells other than Vγ9Vδ2 T cells, through sustained inhibition of farnesyl diphosphate synthase, a key enzyme in the mevalonate pathway [41] . Mevalonate inhibition would induce the production and release of IFNγ by monocytes and macrophages [42] , followed by TNF-α and IL-1β [41, 43] . NBPs also induce leukocyte adherence to endothelial cells and transendothelial migration of mononuclear cells [44] , mediated by increased ICAM-1 expression by monocytes through TNF-α stimulation; this occurs preferentially following intravenous administration [43] . An intriguing observation was that the number of TRAP + /CTR + osteoclasts remained unchanged between the control and ONJ samples, suggesting that the osteoclast differentiation process was not impaired as suggested by Stefanik et al. [31] . However our static analysis provides no indication on osteoclast activity; according to the current literature osteoclast activity in the NBP-treated patients was probably profoundly altered [1] . In these conditions, we hypothesize that ONJ is primarily an aseptic process. Many patients presented with pain and discomfort due to mobile teeth that were extracted despite the lack of clinical or radiological evidence of an infectious process. In our series, some 99 Tc m -MDP scintigraphic follow-up of malignant disease showed radionuclide uptake, and thus bone involvement, well before clinical manifestation onset, showing that early localized bone damage Two grades of inflammation severity (LG: low grade; HG: high grade) were determined after the numbers of inflammatory cells. Except osteocyte data, the parameters were counted in the medullary spaces. ⁎ P = 0.006. ⁎⁎ P = 0.01 vs the control group. ⁎⁎⁎ P = 0.01 vs the LG group. Fig. 6 . Proposed chronological sequence of events underlying ONJ during NBP therapy. A focus of inflammation of unclear origin forms within the bone (visible by radionuclide uptake on scintigraphy) and progresses aseptically to necrosis over a period of several months. Necrosis spreads and reaches the oral mucosa, destroying it and leading to bone exposure. Oral bacteria invade the exposed necrotic bone, aggravating the situation. ONJ is generally diagnosed several weeks after the mucosal breach. The process (and its diagnosis) can be hastened by surgical procedures indicated by unexplained clinical manifestations (pain, tooth mobility, etc.). preceded oral bone exposure. Recently, Raje et al. reported in clinically unaffected sides of the jaws of ONJ patients imaging abnormalities similar to the affected sides [17] , a feature shown here in Fig. 1 (patient  3 ). This fits with Allen and Burr's proposal that bone necrosis precedes clinical manifestation of ONJ [18] . Thus, the unexplained manifestations leading to dental extraction would be the first clinical sign of underlying bone necrosis. Interestingly, cases of bisphosphonaterelated ONJ without bone exposure were recently reported [45, 46] . However, a subclinical infectious origin cannot be totally excluded even if, when mucosal closure was achieved, to protect the bone from the septic oral environment, bone necrosis frequently continued to spread. The early bone radionuclide uptake strongly suggests that bone, and not the mucosa, is the primary target of the NBP-related insult, implying that the observed breakdown of the oral mucosa is secondary to osteonecrosis. Locally high bone concentrations of NBPs would be toxic for adjacent soft tissues, resulting in mucosal disruption [13] . As NBPs inhibit keratinocyte growth by inhibiting the mevalonate pathway [47] , healing of the mucosal breach would be delayed [15] , thus facilitating secondary colonization of the necrotic bone by the oral flora.
This study confirms that ONJ is drug-, dose-and route of administration-dependent [6] . Patients receiving repeated high doses of NBPs were at an increased risk of ONJ. Zoledronic acid is more frequently implicated in ONJ, possibly because of its strong antiresorptive potential [48] . Use of the intravenous route probably results in rapid tissue accumulation [49, 50] and is more deleterious than the oral route. It is noteworthy in this respect that no cases of ONJ occurred in a series of 3105 osteoporotic patients treated for 3 years with 5 mg of zoledronic acid once a year, a dose ten-fold lower than that used to treat metastatic bone disease (4 mg monthly) [51] . Outcome after local treatment was related to the dose and the drug, patients treated with zoledronic acid at a high cumulative dose having the poorest outcome.
In conclusion, our findings in a small patient cohort suggest that an initial focus of damaged bone, which takes up radionuclides, spreads centrifugally both deeper into the jaw and towards the mucosa. The whole process appears to be associated with an inflammatory reaction. A tentative sequence of events is proposed in Fig. 6 . However the exact role of inflammation in this sequence is still not clear; it may be revelatory of other not yet disclosed phenomena. As NBPs are highly beneficial for cancer patients with bone involvement and osteoporotic patients, early markers of bisphosphonate-associated ONJ would be highly useful.
